Last reviewed · How we verify
Marezine (CYCLIZINE)
At a glance
| Generic name | CYCLIZINE |
|---|---|
| Sponsor | GSK |
| Drug class | cyclizine |
| Target | Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
- Allergic conjunctivitis
- Allergic rhinitis
- Common cold
- Cough
- Motion sickness
- Nasal congestion
- Nasal discharge
- Seasonal allergic rhinitis
- Sneezing
- Vasomotor rhinitis
Common side effects
Key clinical trials
- Comparison of the Effect of Cyclizine Versus Metoclopramide on Gastric Residual Volume in Patients Undergoing Bariatric Surgery: A Randomized Double-blinded Clinical Trial
- Cyclizine Vs. Dexamethasone for Nausea and Vomiting Following Intrathecal Morphine in Cases of Cesarean Section (NA)
- Trial to Compare Femoral Nerve Block With Local Anaesthetic Injection for Post-operative Pain After Knee Replacement. (NA)
- Nasal Fentanyl and Buccal Midazolam for Dying Patients (PHASE4)
- Enhanced Recovery After Laparoscopic Sleeve Gastrectomy - a Randomised Controlled Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Marezine CI brief — competitive landscape report
- Marezine updates RSS · CI watch RSS
- GSK portfolio CI